A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis
Phase of Trial: Phase I/II
Latest Information Update: 10 Jan 2019
Price : $35 *
At a glance
- Drugs Vunakizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Jan 2019 Last checked against ClinicalTrials.gov record.
- 02 Jan 2019 Planned number of patients changed from 40 to 194.
- 15 Mar 2018 New trial record